Biosimilars – terms of use

Current Medical Research and Opinion

Volumn 31, Issue 12, 2015, Pages 2325-2330

  Declerck, Paul ^a   Mellstedt, Håkan ^b   Danese, Silvio ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Biologics; Biosimilars; Interchangeability; Pharmacovigilance

Indexed keywords

BIOSIMILAR AGENT; DRUG ANTIBODY; GENERIC DRUG;

CLINICAL DECISION MAKING; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; MEDICAL EDUCATION; MEDICAL TERMINOLOGY; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW;

BIOSIMILAR PHARMACEUTICALS; DRUGS, GENERIC; HUMANS; PHARMACOVIGILANCE;

EID: 84977763676     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1098601     Document Type: Review

References (42)

1. Boone N, Van der Kuy H, Scott M, et al. How to select a biosimilar. Eur J Hosp Pharm 2013;20:275-86
2. Chow SC, Yang LY, Starr A, Chiu ST. Statistical methods for assessing interchangeability of biosimilars. Stat Med 2013;32:442-8. Erratum in: Stat Med 2013;32:3234
3. Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: implications for healthsystem pharmacists. Am J Health Syst Pharm 2013;70:2004-17
4. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood 2012;120:5111-17
5. Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures – 2012. Am J Health Syst Pharm 2012;69:405-21
6. Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Cancer Network 2011;9(Suppl 4):S1-22
7. Rana JB, Chang DY. Pharmacist perception of biosimilar agents in the U.S. Pharmacy Purchas Prod 2012;9:8
8. European Medicines Agency. Guideline on similar biological medicinal products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf [Last accessed June 2015]
9. Crommelin DJA, de Vlieger JSB, Weinstein V, et al. Different pharmaceutical products need similar terminology. AAPS J 2014;16:11-14
10. Wang J, Chow S. On the regulatory approval pathway of biosimilar products. Pharmaceuticals 2012;5:353-68
11. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2011;86:277-88
12. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):13-516
13. European Medicines Agency. EMEA CHMP Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. European Medicines Agency – Europa 2007. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC 500003946.pdf [Last accessed June 2015]
14. World Health Organization. World Health Organization Programme for International Drug Monitoring. World Health Organization. Available at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/index.html#.UD3w-rOzzNM.email [Last accessed June 2015]
15. Calvo B, Zuñiga L. EU’s new pharmacovigilance legislation: considerations for biosimilars. Drug Saf 2014;37:9-18
16. European Medicines Agency Public Assessment Reports. List of Medicines under Additional Monitoring. Available at: http://www.ema.europa.eu/ema/index.jsp?curl¼pages/regulation/document_listing/document_listing_0003 66.jsp&mid=WC0b01ac058067c852 [Last accessed June 2015]
17. Casadevall N, Edwards IR, Felix T, et al. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther 2013;13:1039-47
18. American Pharmacists Association. The biosimilar pathway: where will it lead us? Pharmacy Today 2011;Dec:67-76
19. Declerck P. Biotherapeutics in the era of biosimilars. Drug Safety 2007;30:1087-92
20. World Health Organization Programme on International Nonproprietary Names (INN). Biological Qualifier – An INN Proposal. Available at: http://www.who.int/medicines/services/inn/bq_innproposal201407.pdf [Last accessed June 2015]
21. Ventola CL. Potential concerns and challenges for P&T committees. P&T 2013;38:329-35
22. FDA Information for Healthcare Professionals on Biosimilars. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241719.htm [Last accessed June 2015]
23. Declerck PJ, Darendeliler F, Gòth M, et al. Biosimilars: controversies as illustrated by rhGH. Curr Med Res Opin 2010;26:1219-29
24. Scott BJ, Klein AV, Wang J. Biosimilar monoclonal antibodies: a Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol 2015;55(Suppl 3):S123-32
25. Reinke T. Biosimilars might not measure up to health plan expectations. Manag Care 2012;21:12-13
26. Endrenyi L, Chang C, Chow SC, Tothfalusi L. On the interchangeability of biologic drug products. Stat Med 2013;32:434-41
27. NOR-SWITCH study. Clinical Trials database. Available at: http://clinicaltrials.gov/ct2/show/record/NCT02148640 [Last accessed June 2015]
28. Allen and Ovary. Biosimilar substitution in France: no way back? The Lawyer 2014. Available at: http://www.thelawyer.com/briefings/biosimilarsubstitution-in-france-no-way-back/3014733.article [Last accessed June 2015]
29. AIFA. Position paper. I farmaci biosimilari. Rome. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf [Last accessed June 2015]
30. Biggioggero M, Danova M, Genovese U, et al. The challenging definition of naı¨ve patient for biological drug use. Autoimmun Rev 2015;14:543-6
31. Aapro M. Biosimilars in oncology: current and future perspectives. Generics and Biosimilars Initiative Journal 2013;2:91-3
32. Abraham I, MacDonald K. Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf 2012;11:819-40
33. Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European marketed epoetin alfas: a randomized prospective study. Drugs R D 2011;11:61-75
34. Binocrit European Public Assessment Report. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Conditions_imposed_on_member_states_for_safe_and_effective_use/human/000725/WC500053681.pdf [Last accessed in June 2015]
35. Hlvaaty T, Letkovsky J. Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2014;26:581-7
36. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallelgroup study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20
37. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12
38. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way? Best Pract Res Clin Gastroenterol 2014;28:465-71
39. Pani L, Montilla S, Pimpinella G, Malgarini RB. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. Expert Opin Biol Ther 2013;13:1343-6
40. Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2014;32:5s(abstr LBA4)
41. Danese S, Gomollon F; Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013;7:586-9
42. Arguelles-Arias F, Barreiro-de-Acosta M, Carballo F, et al. Joint position statement by Spanish Society of Gastroenterology and Spanish Society of Pharmacology on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig 2013;105:37-43